How to buy Regeneron Pharmaceuticals stock in Canada

Own Regeneron Pharmaceuticals shares in just a few minutes.

Regeneron Pharmaceuticals is a biotechnology business based in the US. Regeneron Pharmaceuticals shares (REGN) are listed on the NASDAQ and all prices are listed in US Dollars.

Its last market close was $710.00 – an increase of 5.5% over the previous week. Regeneron Pharmaceuticals employs 14,165 staff and has a trailing 12-month revenue of around $13.8 billion.

Our top picks for where to buy Regeneron Pharmaceuticals stock

Best for Beginners

Go to site
Easy to use app
  • $200 or more cash back offer
  • Get 100 free trades
  • Best platform for beginners

Best Overall

Go to site
Low margin rates
  • Access to international stock exchanges
  • Low margin rates
  • Powerful research tools

Best for Low Fees

Go to site
CA & US trading
  • 6% cash rebate plus $2,200 in trading perks
  • Low transaction fees
  • Easy-to-use app

How to buy Regeneron Pharmaceuticals stock

  1. Choose a stock trading platform. Compare investment platforms.
  2. Open an account. Provide your personal information and sign up.
  3. Fund your account. Deposit funds into your account by linking your banking information or transfer funds from another trading account.
  4. Search for the stock name – REGN. Search for the stock by name or ticker symbol.
  5. Buy the stock. Place your order. It's that simple.

Buy Regeneron Pharmaceuticals, Inc. stock from these online trading platforms

Compare special offers, low fees and a wide range of investment options among top trading platforms.

Note: The dollar amounts in the table below are in Canadian dollars.

1 - 6 of 6
Product CAFST Finder Score Available Asset Types Account Types Stock Trading Fee Account Fee Offer
Interactive Brokers logo
Finder Score
Stocks, Bonds, Options, Index Funds, ETFs, Currencies, Futures
RRSP, TFSA, Personal, Joint
min $1.00, max 0.5%
$0
CIBC logo
Finder Score
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, Precious Metals, IPOs
RRSP, RESP, RRIF, TFSA, Personal, Joint
$6.95
$0 if conditions met, or $100
Get 100 free trades when you open a CIBC Investor’s Edge account using promo code EDGE2425. Plus, get $200 or more cash back. Valid until March 31, 2025.
Moomoo logo
Finder Score
Stocks, Options, ETFs
RRSP, TFSA, Personal
$0.014/stock
$0
Enjoy a 6% cash rebate, plus $2,200 in trading perks.
RBC Direct Investing logo
Finder Score
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, Precious Metals, IPOs
RRSP, RESP, RRIF, TFSA, Personal, Joint, Business
$6.95 - $9.95
$0 if conditions met, otherwise $25/quarter
Get a $300 cash bonus and up to 500,000 Avion points when you open your first eligible RBC Direct Investing account. Plus, get 50 commission-free trades to use within one year of account opening. Conditions apply. Offer ends March 3, 2025
Questrade logo
Finder Score
Stocks, Bonds, Options, Mutual Funds, ETFs, Forex, GICs, Precious Metals, IPOs
RRSP, RESP, RRIF, TFSA, Personal
$4.95 - $9.95
$0
Qtrade logo
Finder Score
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
RRSP, RESP, RRIF, TFSA, Personal, Joint
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Get 1% cashback or more, a $150 sign-up bonus & unlimited free trades until April 30th, 2025.
loading

Finder Score for stock trading platforms

To make comparing even easier we came up with the Finder Score. Trading costs, account fees and features across 10+ stock trading platforms and apps are all weighted and scaled to produce a score out of 10. The higher the score the better the platform - simple.

Read the full methodology

Regeneron Pharmaceuticals stock price (NASDAQ: REGN)

Use our graph to track the performance of REGN stocks over time.

Regeneron Pharmaceuticals stocks at a glance

Information last updated 2025-02-07.
Latest market close$710.00
52-week range$642.00 - $1,211.20
50-day moving average $720.14
200-day moving average $945.25
Wall St. target price$939.37
PE ratio 18.8333
Dividend yield N/A
Earnings per share (TTM) $38.34

Is it a good time to buy Regeneron Pharmaceuticals stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

This chart is not advice or a guarantee of success. Rather, it gauges the real-time recommendations of three popular technical indicators: moving averages, oscillators and pivots. Finder is not responsible for how your stock performs.

Regeneron Pharmaceuticals price performance over time

Historical closes compared with the close of $722.07 from 2025-02-06

1 week (2025-01-31) 7.29%
1 month (2025-01-08) -1.57%
3 months (2024-11-08) -12.84%
6 months (2024-08-08) -35.14%
1 year (2024-02-08) -23.71%
2 years (2023-02-08) -3.68%
3 years (2022-02-08) 16.85%
5 years (2020-02-07) 89.09%

Is Regeneron Pharmaceuticals stock undervalued or overvalued?

Valuing Regeneron Pharmaceuticals stock is incredibly difficult, and any metric has to be viewed as part of a bigger picture of Regeneron Pharmaceuticals's overall performance. However, analysts commonly use some key metrics to help gauge the value of a stock.

Regeneron Pharmaceuticals's P/E ratio

Regeneron Pharmaceuticals's current share price divided by its per-share earnings (EPS) over a 12-month period gives a "trailing price/earnings ratio" of roughly 19x. In other words, Regeneron Pharmaceuticals shares trade at around 19x recent earnings.

That's relatively low compared to, say, the trailing 12-month P/E ratio for the NASDAQ 100 at the end of 2019 (27.29). The low P/E ratio could mean that investors are pessimistic about the outlook for the stock or simply that they're under-valued.

Regeneron Pharmaceuticals's PEG ratio

Regeneron Pharmaceuticals's "price/earnings-to-growth ratio" can be calculated by dividing its P/E ratio by its growth – to give 1.152. A low ratio can be interpreted as meaning the stocks offer better value, while a higher ratio can be interpreted as meaning the stocks offer worse value.

The PEG ratio provides a broader view than just the P/E ratio, as it gives more insight into Regeneron Pharmaceuticals's future profitability. By accounting for growth, it could also help you if you're comparing the stock prices of multiple high-growth companies.

Regeneron Pharmaceuticals's EBITDA

Regeneron Pharmaceuticals's EBITDA (earnings before interest, taxes, depreciation and amortisation) is $4.6 billion.

The EBITDA is a measure of a Regeneron Pharmaceuticals's overall financial performance and is widely used to measure a its profitability.

Regeneron Pharmaceuticals financials

Revenue TTM $13.8 billion
Operating margin TTM 33.43%
Gross profit TTM $7 billion
Return on assets TTM 7.41%
Return on equity TTM 17.17%
Profit margin 33.61%
Book value $272.04
Market Capitalization $78.9 billion

TTM: trailing 12 months

Regeneron Pharmaceuticals's environmental, social and governance track record

Environmental, social and governance (known as ESG) criteria are a set of three factors used to measure the sustainability and social impact of companies like Regeneron Pharmaceuticals.

When it comes to ESG scores, lower is better, and lower scores are generally associated with lower risk for would-be investors.

Regeneron Pharmaceuticals's total ESG risk score

Total ESG risk: 22.33

Socially conscious investors use ESG scores to screen how an investment aligns with their worldview, and Regeneron Pharmaceuticals's overall score of 22.33 (as at 12/31/2018) is pretty good – landing it in it in the 27th percentile of companies rated in the same sector.

ESG scores are increasingly used to estimate the level of risk a company like Regeneron Pharmaceuticals is exposed to within the areas of "environmental" (carbon footprint, resource use etc.), "social" (health and safety, human rights etc.), and "governance" (anti-corruption, tax transparency etc.).

Regeneron Pharmaceuticals's environmental score

Environmental score: 1.51/100

Regeneron Pharmaceuticals's environmental score of 1.51 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector terms of its environmental impact, and exposed to a lower level of risk.

Regeneron Pharmaceuticals's social score

Social score: 13.94/100

Regeneron Pharmaceuticals's social score of 13.94 puts it squarely in the 2nd percentile of companies rated in the same sector. This could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to taking good care of its workforce and the communities it impacts.

Regeneron Pharmaceuticals's governance score

Governance score: 5.88/100

Regeneron Pharmaceuticals's governance score puts it squarely in the 2nd percentile of companies rated in the same sector. That could suggest that Regeneron Pharmaceuticals is a leader in its sector when it comes to responsible management and strategy, and exposed to a lower level of risk.

Regeneron Pharmaceuticals's controversy score

Controversy score: 2/5

ESG scores also evaluate any incidences of controversy that a company has been involved in. Regeneron Pharmaceuticals scored a 2 out of 5 for controversy – the second-highest score possible, reflecting that Regeneron Pharmaceuticals has, for the most part, managed to keep its nose clean.

Environmental, social, and governance (ESG) summary

Regeneron Pharmaceuticals Inc was last rated for ESG on: 2019-01-01.

Total ESG score 22.33
Total ESG percentile 26.82
Environmental score 1.51
Environmental score percentile 2
Social score 13.94
Social score percentile 2
Governance score 5.88
Governance score percentile 2
Level of controversy 2

Regeneron Pharmaceuticals stock dividends

We're not expecting Regeneron Pharmaceuticals to pay a dividend over the next 12 months.

Regeneron Pharmaceuticals stock price volatility

Over the last 12 months, Regeneron Pharmaceuticals's stocks have ranged in value from as little as $642 up to $1211.2. A popular way to gauge a stock's volatility is its "beta."

Beta is a measure of a stocks volatility in relation to the market. The market (NASDAQ average) beta is 1, while Regeneron Pharmaceuticals's is 0.142. This would suggest that Regeneron Pharmaceuticals's stocks are less volatile than average (for this exchange).

Regeneron Pharmaceuticals overview

Regeneron Pharmaceuticals, Inc. discovers, invents, develops, manufactures, and commercializes medicines for treating various diseases worldwide. The company's products include EYLEA injection to treat wet age-related macular degeneration and diabetic macular edema; myopic choroidal neovascularization; diabetic retinopathy; neovascular glaucoma; and retinopathy of prematurity. It also provides Dupixent injection to treat atopic dermatitis and asthma in adults and pediatrics; Libtayo injection to treat metastatic or locally advanced cutaneous squamous cell carcinoma; Praluent injection for heterozygous familial hypercholesterolemia or clinical atherosclerotic cardiovascular disease in adults; REGEN-COV for covid-19; and Kevzara solution for treating rheumatoid arthritis in adults. In addition, the company offers Inmazeb injection for infection caused by Zaire ebolavirus; ARCALYST injection for cryopyrin-associated periodic syndromes, including familial cold auto-inflammatory syndrome and muckle-wells syndrome; and ZALTRAP injection for intravenous infusion to treat metastatic colorectal cancer; and develops product candidates for treating patients with eye, allergic and inflammatory, cardiovascular and metabolic, infectious, and rare diseases; and cancer, pain, and hematologic conditions. It has collaboration with Mammoth Biosciences, Inc. to research, develop and commercialize in vivo CRISPR-based gene editing therapies for multiple tissues and cell types; and with Sonoma Biotherapeutics, Inc.

Frequently asked questions

What percentage of Regeneron Pharmaceuticals is owned by insiders or institutions?
Currently 1.57% of Regeneron Pharmaceuticals stocks are held by insiders and 90.728% by institutions.
How many people work for Regeneron Pharmaceuticals?
Latest data suggests 14,165 work at Regeneron Pharmaceuticals.
When does the fiscal year end for Regeneron Pharmaceuticals?
Regeneron Pharmaceuticals's fiscal year ends in December.
Where is Regeneron Pharmaceuticals based?
Regeneron Pharmaceuticals's address is: 777 Old Saw Mill River Road, Tarrytown, NY, United States, 10591-6707
What is Regeneron Pharmaceuticals's ISIN number?
Regeneron Pharmaceuticals's international securities identification number is: US75886F1075
What is Regeneron Pharmaceuticals's CUSIP number?
Regeneron Pharmaceuticals's Committee on Uniform Securities Identification Procedures number is: 75886F107
Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site